Lọc theo
An 8-week exercise-based prehabilitation program helps enhance exercise capacity, muscle function, and muscle size in kidney transplant candidates, including those with frailty, according to the FRAILMar study.
Bimagrumab, when combined with semaglutide, enhances weight loss while preserving lean mass better than either treatment alone in the phase IIb BELIEVE study presented at ADA 2025.
New drug applications approved by US FDA as of 16-31 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
New drug applications approved by US FDA as of 1-15 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
New research suggests that in older adults with type 2 diabetes (T2D) who are taking metformin, using dipeptidyl peptidase-4 inhibitors (DPP4is) and glucagon-like peptide-1 receptor agonists (GLP1RAs) has a null effect on the risk of COVID-19 infection. However, among those who do contract the virus, the use of these drugs appears to lower the risk of hospitalization.
Frailty appears to be a familiar feature among patients with multiple forms of vasculitis, suggesting a substantial subset of patients at risk for worse outcomes, suggests a study.
A recent study in the Philippines has identified key demographic and behavioural patterns among Filipino men who have sex with men (MSM) and transgender individuals (TGIs) regarding their awareness of pre-exposure prophylaxis (PrEP) and modality preferences.
Extended durations of lactation appear to reduce the risk of maternal coronary artery disease (CAD) diagnosed before age 70 years, according to a study.
A systematic review and meta-analysis show persistence of retinal fluid (RF) up to 2 years after anti-VEGF treatment for neovascular age-related macular degeneration (nAMD).
A recent study suggests that the use of hormone therapy does not contribute to increased women with severe symptoms of COVID-19.